Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of once-weekly PB1046 (Vasomera) for symptomatic pulmonary arterial hypertension
2019-001598-10Phase 2Terminated
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bazedoxifene + conjugated estrogens in pulmonary arterial hypertension (PAH) (2 arms), sponsored by PhaseBio Pharmaceuticals. Started Dec 2019; status: terminated.
02
Drugs
bazedoxifene + conjugated estrogens
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2019-001598-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001598-10.